Harrow Health Acquires Rights to 4 Branded Eye Drops

IOPIDINE® 1% and 0.5% (apraclonidine hydrochloride), and MAXITROL® (neomycin and polymyxin B sulfate and dexamethasone) 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5% (moxifloxacin hydrochloride), from Novartis. The acquired products, which will be sold, marketed, and distributed through Harrow’s wholly owned subsidiary, ImprimisRx, combined with the Company’s existing ophthalmic‑focused product portfolio, support Harrow’s growing ophthalmic surgical and acute care market presence.